⌕
Veracyte · VCYT · Nasdaq
Tenet 78 · Strong
Compare
$24.01−1.32%At closeTenet 78 · Strong
$24.01−0.32 (−1.32%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Veracyte (VCYT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 12, 2026 · 10:09 ETCOMPANY'S OWN WORDS
Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky

Needham reportedly cut its Veracyte price target by $23 per share after the Company's November 4, 2026 outlook reset on its Decipher Prostate test. An investigation into potential securities law violations is underway on…

● Seeking AlphaNov 12, 2026 · 09:57 ETEARNINGS EXPECTED BY FEB 24
Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo

Veracyte is rated Hold, as its valuation premium has vanished, but growth prospects have weakened, especially for Decipher prostate cancer testing. Decipher's test volume growth is slowing sharply, with management now pl…

● Seeking AlphaNov 10, 2026 · 19:11 ET
Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript

Veracyte, Inc. ( VCYT ) 2026 UBS Global Healthcare Conference November 10, 2026 4:15 PM EST Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call Participants Douglas Sc…

● GlobeNewsWireNov 10, 2026 · 10:11 ETEARNINGS EXPECTED BY FEB 24
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)

Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investiga…

● Business WireNov 9, 2026 · 16:22 ET
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $VCYT--VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law.…

● Defense WorldNov 8, 2026 · 04:13 ET
Veracyte (NASDAQ:VCYT) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Veracyte, Inc. (NASDAQ: VCYT - Get Free Report) saw unusually-high trading volume on Friday. 1,904,920 shares traded hands during trading, an increase of 57% from the average daily volume of 1,211,597 shares. T…

● Zacks Investment ResearchNov 6, 2026 · 13:10 ETEARNINGS EXPECTED BY FEB 24
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment

VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.…

● PRNewsWireNov 6, 2026 · 10:13 ETEARNINGS EXPECTED BY FEB 24
VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte

/PRNewswire/ -- A $100 million buyback authorization and $151.8 million in third-quarter revenue did not hold up Veracyte, Inc. (NASDAQ: VCYT) shares, which…

● Seeking AlphaNov 5, 2026 · 23:54 ETEARNINGS EXPECTED BY FEB 24
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript

Veracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite -…

● PRNewsWireNov 5, 2026 · 19:34 ETCOMPANY'S OWN WORDS
Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)

Veracyte stock fell more than 50% after the Company reported on November 4, 2026 that Decipher Prostate volume fell short of its expectations. Levi and Korsinsky investigates into potential securities law violations.…

● GlobeNewsWireNov 5, 2026 · 16:58 ET
VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc.

VCYT's stock is down more than 50%; Ademi LLP is investigating Veracyte for potential securities fraud. CLICK HERE TO JOIN  MILWAUKEE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities frau…

● MarketBeatNov 5, 2026 · 04:17 ETEARNINGS EXPECTED BY FEB 24
What Veracyte (VCYT) Said on Its Q3 Earnings Call

Veracyte NASDAQ: VCYT reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management's forecast. The company also ou…

● Zacks Investment ResearchNov 4, 2026 · 20:51 ETEARNINGS EXPECTED BY FEB 24
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.51 per share a year ago.…

● GlobeNewsWireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 24
Veracyte Announces Third Quarter 2026 Financial Results

Grew total revenue to  $151.8 million and testing revenue to $146.4 million , representing 15% year-over-year growth Announces $100 million share repurchase program SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSW…

● GlobeNewsWireOct 29, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences: UBS Glob…

● Zacks Investment ResearchOct 28, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 24
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● GlobeNewsWireOct 23, 2026 · 04:00 ET
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in clinically very high-risk…

● Zacks Investment ResearchOct 21, 2026 · 13:11 ETEARNINGS EXPECTED BY FEB 24
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?

Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.…

● Defense WorldOct 20, 2026 · 03:41 ET
Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?

Veracyte, Inc. (NASDAQ: VCYT - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $45.25 and traded as low as $43.45. Veracyte shar…

● GlobeNewsWireOct 19, 2026 · 08:00 ET
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the Eu…

● GlobeNewsWireOct 16, 2026 · 09:15 ET
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients w…

● GlobeNewsWireOct 14, 2026 · 16:05 ETEARNINGS EXPECTED BY FEB 24
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after …

● GlobeNewsWireSep 29, 2026 · 08:00 ET
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized p…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 24. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just VCYT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.